TP53 and acute myeloid leukemia: For patients with biallelic TP53 inactivation in the WHO-2022 criteria, MDS (n = 17) or MDS/AML (n = 29) with mutated TP53 in the ICC (Supplementary Table 7) exhibited a similar prognosis (3.9 vs. 4.0 months for LFS, P = 0.211; 4.4 vs. 7.0 months for OS, P = 0.293) (Supplementary Fig. 11).